All Posts

medtech-news-for-lensgen-ge-nevro-hyperfine-immunexpress
LensGen’s Juvene Intraocular Lens; Nevro announces clinical data publications; FDA Clearance to Immunexpress’s SeptiCyte; GE unveils AI and Digital Technologies; Canon launches PIQE DLR and SilverBeam; Hyperfine’s Swoop gets FDA clearance

Canon Medical launches super-resolution deep-learning reconstruction for Cardiac CT scans  On November 28, 2021, Canon Medical launched the Precise IQ Engine (PIQE) DLR and SilverBeam filter in the recent version of the Aquilion ONE / PRISM edition. PIQE, super-resolution deep-learning reconstruction techno...

Find More

mobile-apps-for-mental-health
Plotting the Extensive Demand of Mobile Apps for Mental Health

Mental health services in the new technology-driven world offer so many options. Many of these options are accessible via intuitive apps that are designed to streamline the mental health journey and take most of the guesswork out of finding the expert attention. Most of these apps allow to access the features at an...

Find More

pharma-news-for-ge-optellum-therapixel-ocugen-blueprint
GE Healthcare-Optellum’s collaboration; Ocugen’s Covid-19 vaccine trial; Blueprint to acquire Lengo Therapeutics; Therapixel’s Mammoscreen

GE Healthcare, Optellum collaborate for AI-based lung cancer diagnosis GE Healthcare has collaborated with Optellum to progress precision diagnosis and lung cancer treatment with artificial intelligence. The partnership is zeroed in on helping healthcare providers to evaluate the malignancy of a lung nodule a...

Find More

Neuromodulation-Devices-Migraine
Neuromodulation Devices Observed to Reshape the Migraine Treatment Dynamics

Migraine is the most commonly encountered disabling disorder that can be featured as attacks of severe, unilateral, and a pulsating form of headache composed of symptoms such as photophobia, phonophobia, nausea, vomiting, and cutaneous allodynia. As per the Migraine Research Foundation 2021, Migraine is considered ...

Find More

Avrobios-Gene-Therapy-for-Cystinosis
Avrobio’s Gene Therapy for Cystinosis Treatment: A New Hope to Overcome the Existing Medical Unmet Needs

Cystinosis is a genetic condition that causes the buildup of the amino acid "cystine" in the cells of the body is known as cystinosis. Due to the excessive accumulation of cystine in various cells, organs, tissues, including the kidneys, eyes, liver, thyroid, muscles, pancreas, brain, and white blood cells of the b...

Find More

medtech-news-for-neurent-theradaptive-hagar-fujifilm-brain-navi
Neurent Medical’s NEUROMARK; Brain Navi NaoTrac received European CE Mark approval; Theradaptive receives Breakthrough Medical Device Designation; HAGAR GWave awarded Breakthrough Device Designation; Fujifilm launches ColoAssist PRO

Neurent Medical obtains FDA Clearance for NEUROMARK™, a novel multi-point Nerve Disruption Treatment for Chronic Rhinitis   On November 18, 2021, Neurent Medical, a company working in developing treatments for chronic inflammatory sino-nasal diseases, received clearance from the Food and Drug Ad...

Find More

value-based-healthcare-model
Evaluating the Essential Factors Building the Value-Based Healthcare Model

Value-based healthcare is a healthcare delivery model or a process in which the providers, including hospitals and physicians, are paid based on patient health outcomes. It is one of the alternative models that offer value and also has the potential to transform and improve healthcare delivery in each and every reg...

Find More

pharma-news-for-bluebird-bio-fda-twist-bioscience-sosei-heptares
Bluebird bio may get gene therapy approved in the US; Neurocrine pens $2.6B pact with Sosei Heptares; FDA opens clearances for hepatitis C diagnostics; Twist nabs antibody discovery biotech Abveris for $190M

Bluebird bio may finally get a gene therapy approved in the US Bluebird bio may get gene therapy approved in the US. The Cambridge, MA biotech declared that the FDA had accepted and given priority review for Zynteglo, its gene therapy for the rare blood disorder beta-thalassemia. The announcement sets up an expe...

Find More

follicular-lymphoma-treatment-scenario
Diverse Pipeline Therapies to Glide the Follicular Lymphoma Treatment Market

Follicular Lymphoma is the second most widespread non-Hodgkin lymphoma subtype, accounting for roughly 20% of all NHL cases. It is a slow-growing (low-grade) NHL that develops from B cells. It is called follicular lymphoma because the abnormal B cells usually develop in clumps called ‘follicles’ inside lymph nodes....

Find More

medtech-news-and-updates-for-abbott-ivantis-medtronic-alung-appliedvr-orthalign
Abbott’s Pacemaker System; Ivantis’s Hydrus Microstent; Medtronic’s PillCam Small Bowel 3; ALung Technologies’s Hemolung; AppliedVR’s EaseVRx; J&J to split into two companies; OrthAlign’s Lantern® launch; LumiThera’s Light-based Theranostic

J&J intends to split into two companies, separating consumer products and pharmaceutical businesses  On November 12, 2021, Johnson & Johnson announced its plans to split the Company’s Consumer Health business, forming a new publicly traded company. This will help the company create two global leaders tha...

Find More